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ABSTRACT 
Objective: The objective of present study was to evaluate incidence and risk factors for the development of new-onset diabetes after 
transplantation (NODAT) after kidney transplantation at our center. 
Methods: A total 79 nondiabetic patients who underwent living donor kidney transplantation from January 2014 to August 2014 were 
prospectively enrolled. All the patients were followed for one year. All the patients received the same protocol of immunosuppressive therapy. 
NODAT was defined as if a patient had HbA1c ≥ 6.5%, fasting venous plasma glucose ≥126 mg/dl, or was receiving diet or medical therapy for 
diabetes. 
Results: The incidence of NODAT was 29.9% after one year. Risk factors associated with the development of NODAT included older age (OR: 1.07; 
p<0.05), family history (OR: 3.58; P<0.05), hepatitis C virus (HCV) positivity (OR: 11.15; p<0.05), obesity (OR: 4.28; p<0.05), pre-transplant 
triglycerides (OR: 1.01; p<0.005) and cholesterol level (OR: 1.01; p<0.005). 
Conclusion: The prevalence of potentially modifiable risk factors in our study cohort was overweight recipients and pretransplant HCV infection, 
serum triglycerides, and cholesterol levels. 
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INTRODUCTION 
New-onset diabetes after transplantation (NODAT) is a common and 
clinically important complication of solid organ transplantation 
including kidney transplantation. NODAT is associated with reduced 
long-term patient and graft survival [1, 2]. NODAT can increase the 
risk of cardiovascular disease by two to three fold compared with 
nondiabetic patients [3]. The incidence of NODAT after solid organ 
transplantation varies from 2% to 53% in the first transplant year 
[4]. The development of NODAT is a well-known complication of 
renal transplant patients with very much higher incidences of 15 to 
25% in the first year after transplantation, compared with 
subsequent annual incidence(4-6%) [5]. Despite the apparently high 
incidence of NODAT after transplantation, transplant patients are 
not always routinely screened for hyperglycemia posttransplant and 
the condition is often underestimated [6]. There are various risk 
factors for NODAT, which include older age, recipient male gender, 
ethnicity, higher BMI, immunosuppressive use, family history of type 
2 diabetes (T2DM), hepatitis C seropositivity, cytomegalovirus 
(CMV) infection, acute rejection (AR) history, male donor, and 
elevations in pretransplant fasting glucose and triglycerides [2, 7, 8]. 
The aim of the present study was to determine the incidence of 
NODAT and to assess modifiable risk factors for the development of 
NODAT at 12 mo in Indian population potentially. 
MATERIALS AND METHODS 
This single-center prospective observational study was carried out 
at the MuljibhaiPatel Urological Hospital, Nadiad, Gujarat, India. All 
the recipients, who underwent living donor renal transplantation 
from January 2014 to July 2014, were included for the analysis. A 
total of 104 patients was transplanted during this period. Seventy-
seven patients were eligible for the study. Reasons for exclusion 
were pre-transplant diabetes Mellitus (n=25), death within the first 
month of transplantation (n=1) and graft loss within 2 w of 
transplantation (n=1). All the patients were followed up for at least 
one year. Ethical approval was obtained from the Institute Ethics 
Committee of Muljibhai Patel Society for Research in Nephro-
Urology, and informed consent was obtained from all the patients.  
NODAT definition[5] 
NODAT was defined as if a patient had HbA1c ≥ 6.5%, fasting venous 
plasma glucose ≥ 126 mg/dl, or was receiving diet or medical 
therapy for diabetes between 1 mo and one-year post transplant.  
Immunosuppressant 
A total of 63 (81.8%; table 1) patients had been offered either 
basiliximab or anti-thymocyte globulin (ATG) as induction therapy. 
Basiliximab was administered in a dose of 20 mg intravenously 2 h 
before transplantation and on day four after the operation. 
Treatment with ATG was initiated intraoperatively, before graft 
reperfusion. The dose of ATG varied from 1.5 mg/kg to 6 mg/kg and 
was administered either as a bolus or as divided doses. Throughout 
the study, all patients received a triple immunosuppressive regimen 
consisting of tacrolimus, steroids, and mycophenolate mofetil (MMF) 
as, maintenance therapy. Pulse methylprednisolone (1g) was given 
intravenously to all patients on day 0. Oral prednisolone was 
subsequently prescribed, starting at 1.0 mg/kg and tapered to 7.5–
10 mg/d. MMF (2000 mg/d) was administered orally from the day-
2. MMF was continued throughout the study if possible, but the dose 
was reduced or discontinued in the event of suspected toxicity, 
according to clinical judgment. Tacrolimus trough levels of 5–10 
ng/ml were targeted for the initial two months and levels of 3–7 
ng/ml was targeted thereafter in both groups. All the recipients 
received prophylaxis for CMV, i.e., Oral valganciclovir for 3-6 mo and 
for Pneumocystis Pneumonia, i.e., cotrimoxazole for 6–12 mo.  
Clinical evaluation 
The demographic and baseline data gathered included the age, weight, 
genders of the recipient and donor, HLA (Human leukocyte antigen) 
mismatch, baseline serum creatinine level, native kidney disease, the 
number of transplantation and type of living donor (related or Other 
than related). Tacrolimus trough level and serum creatinine level were 
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recorded on days 0 and 7 and months 1, 3, 6, 9 and 12. AR was diagnosed 
either clinically or through biopsies. AR episodes were treated either 
with intravenous courses of methylprednisolone (500–1000 mg) or with 
monoclonal antibodies, depending on the severity of rejection. 
 




Male 58 (75.3) 
Female 19 (24.7) 
Weight 54.9±10.9 
Time on dialysis (in month) 4.4 
Preemptive transplantation 18(23.4) 




Male 27 (35.1) 
Female 50 (64.9) 
Living other than related  20 (25.9) 
Native kidney disease 
CGN 14 (18.2) 
Polycystic kidney disease 4 (5.2) 
Interstitial nephritis 6 (7.8) 







Antithymocyte globulin 35(55.6) 
Mean baseline Serum creatinine (mg/dl) 4.11±1.7 
Data are expressed as mean values, with Plus–minus values as standard deviation (SD), or as numbers, with percentages in parentheses 
 
Statistical analysis 
Statistical analysis was performed using MedCalc15.4. Categorical 
variables were summarized as total number and percentages, and 
continuous variables were summarized as means with standard 
deviations. Categorical data were compared using Fisher’s exact test, 
and continuous variables were compared using the unpaired 
Student t-test. P<0.05 was considered statistically significant. 
RESULTS 
The baseline demographic characteristics of the recipients are 
presented in table 1. The mean age of patients at transplantation 
was 35.97 y, including 64.5% below 40 y and 35.5% above 40 y of 
age. There were 58 males and 19 females in the study cohort. Five 
patients were hepatitis C virus (HCV) positive before 
transplantation. The majority of donors were females (64.9%) and 
only 27 (35.1%) donors were males. The mean age of living donor 
was 50. A total of twenty patients (25.9%) underwent living other 
than related transplantation while the rest of all recipients received 
living-related transplantation. Haemodialysis was the pretransplant 
modality in all the patients, whereas eighteen patients (23.4%) 
received pre-emptive transplantation. During the study period, ten 
patients had acute rejection episodes, which were successfully 
treated with IV methylprednisolone and monoclonal antibodies. 
At 12 mo, 23 (29.9%) patients developed NODAT. Among which 13 
patients were given oral hypoglycemic agents, while insulin was 
prescribed to 10 patients for the treatment of post-transplant diabetes.
 
Table 2: Characteristic of patients with or without diabetes 
 NODAT  (n=23) No NODAT  (n=54) P value 
Non-Modifiable risk factors 
Age 37.91±7.69 34.24±7.23 0.0245
Male 
* 
14 (60.7) 42(77.8) 0.1643 
Positive family history of diabetes 8 (34.8) 6(11.1) 0.0225
Modifiable risk factors 
* 
BMI at transplant (>25 kg/m2 7 (30.4) ) 5 (9.3) 0.0352
Pre-Tx HCV positivity 
* 
4 (17.4) 1 (1.2) 0.0259
Mean Pre-Tx cholesterol levels (mg/dl) 
* 
204.3±54.55 171.06±45.07 0.0144
Mean Pre-Tx triglyceride levels (mg/dl) 
* 
149.78±77.73 106.9±55.84 0.01485
Positive CMV infections 
* 
3 (13) 4 (7.4) 0.4203 
Acute rejection (yes) 5 (21.7) 5 (9.3) 0.1541 
Mean Trough Tacrolimus level (ng/ml) 6.55±1.57 6.42±2.37 0.4041 
P value finds by fisher exact test or by unpaired t test.; data are expressed as mean values, with Plus–minus values as standard deviation(SD), or as 
numbers, with percentages in parentheses; *
 
statistically significant; Tx, Transplantation; HCV, hepatitis C virus; CMV, Cytomegalovirus; HCV, 
Hepatitis C Virus. 
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Table 2 shows a comparison of potential risk factors for NODAT in 
patients of both the groups. The occurrence of NODAT was 
significantly higher in patients with older age (37.91±7.69 y versus 
34.24±7.23 y; p<0.05). The Odd ratio (OR) for the development of 
NODAT by univariate logistic regression analysis was 1.07 (95% CI, 
0.9989-1.1486; p<0.05; table 3). Positive family history was 
important risk factors for NODAT (OR: 3.58; 95% CI: 1.1124-
11.5277; p<0.05; table 3). Patients with NODAT displayed greater 
BMI (21 kg/m2 versus 18 kg/m2) and were more frequently 
overweight (p<0.05) as compared to patients without NODAT. Odd 
ratio for the development of NODAT was 4.28 (95% CI: 1.1934-
15.408) among patients with>25 kg/m2
 
 BMI. Likewise, risk 
factors such as pre-transplant HCV infections (OR: 11.15; 95% 
CI: 1.0051-106.19; p<0.05), pre-transplant serum cholesterol 
levels (204.3±54.55 mg/dl versus 171.06±45.07 mg/dl; p<0.05) 
and triglyceride levels (149.78±77.73 mg/dl versus 106.9±55.84 
mg/dl; p<0.05) were significantly higher in patients with 
NODAT. 
 
Table 3: Univariate logistic regression analysis of risk factors for NODAT 
OR 95% CI P value 
Age 1.07 0.9989-1.1486 0.0460 
Positive family history of diabetes 3.58 1.1124-11.5277 0.0326 
BMI at transplant (>25 kg/m2 4.28 ) 1.1934-15.408 0.0257 
Pre-Tx HCV positivity 11.15 1.0051-106.19 0.0160 
Mean Pre-Tx cholesterol levels (mg/dl) 1.01 1.0049-1.0288 <0.005 
Mean Pre-Tx triglyceride levels (mg/dl) 1.0147 1.0051-1.0288 <0.005 
CI, Confidence interval; OR, Odd ratio 
 
Mean trough tacrolimus levels and prevalence of CMV infections 
were higher with NODAT cohort as compared to patients without 
NODAT, but the differences were not significant. The majority of 
patients (78.3%) had NODAT within three months after 
transplantation while very few patients (21.7%) were diagnosed 
with diabetes within six months of transplantation. 
DISCUSSION 
NODAT is a serious metabolic complication after solid organ 
transplantation with an incidence ranging from 2-53 % after one 
year of transplantation [9]. The incidence of NODAT in the present 
study was 29.9% after one year. There are mainly two types of risk 
factors responsible for NODAT: Modifiable and Non-Modifiable risk 
factors. Modifiable risk factors include overweight recipients, 
immunosuppressive therapy, HCV infection, CMV infection, 
pretransplant hypertriglyceridemia and hypercholesterolemia. Non-
modifiable risk factors include Ethnicity, older age (>40 y), male 
recipient, positive family history of diabetes, deceased donor, the 
presence of polycystic kidney disease, and impaired fasting glucose 
levels. 
Our study demonstrates that using American Diabetes Association 
(ADA) criteria for the diagnosis of diabetes, the incidence of NODAT is 
higher than a previously reported study using arbitrary criteria. The 
present study confirmed previously reported several risk factors but 
was unable to confirm others. Of all risk factors, only overweight, HCV 
infection and triglyceride levels are potentially modifiable 
The incidence of diabetes after transplantation is greater in older 
age patients [10]. According to Cosio et al., older recipients with 
more than 45 y are 2.9 times more likely to develop diabetes [11]. In 
the present study, thirteen percent of patients over the age of 45 y 
developed diabetes. Likewise, obese (>30 kg/m2) or overweight (25-
30 kg/m2 12) patients have a higher risk of developing NODAT [ , 13]. 
Thirty-nine percent of patients were weighing more than 60 kg at 
the time of transplantation while 26% of patients below 50 kg 
developed NODAT. Seventeen percent of patients in the group over 
the age of 45 y and weighing more than 65 kg developed NODAT. 
Chakkera et al. found that pre-transplant elevated serum 
triglyceride levels as an important risk factor for post-transplant 
diabetes development (P<0.05, OR: 1.61) [5]. Similarly, the mean 
triglyceride level was significantly higher in patients with NODAT 
compared to patients without NODAT (OR: 1.012; CI: 1.0051-1.0288: 
p<0.005; table 3) in the present study. Additionally, mean serum 
cholesterol level was also significantly higher in patients with 
NODAT (OR: 1.02; CI: 1.0049-1.0288: p<0.05; table 3). 
Immunosuppressive therapy is responsible for 74% risk of 
developing NODAT [9]. Steroids are clearly associated with NODAT 
and are related to cumulative dosages and therapy duration [14]. In 
accordance, the beneficial effect of steroid-sparing regimen on the 
incidence of NODAT has been studied in the various studies [15]. As 
per our hospital protocol, steroid-free immunosuppressive therapy 
does not practice and effect of cumulative doses of steroids at the 
time of occurrence of NODAT was not analyzed in the present study. 
Hence effects of this important factor, on the risk of development of 
NODAT, could not be studied. The present study could not find a 
significant difference of trough tacrolimus level between two groups 
(6.55±1.57 ng/ml versus 6.42±2.37 ng/ml; P>0.05). Therefore, 
tacrolimus level was not associated with increased risk of 
development of NODAT in our study cohort. It is consistent with 
previous studies by Prakash et al. [16] and Bora et al.[17] In contrast 
to this, Shah et al. found a significant correlation between tacrolimus 
levels and incidence of NODAT [13]. 
HCV infection is significant comorbidity in kidney transplant 
recipients, occurring in 10% to 40% of patients, and it is associated 
with an increased risk of both graft failure and mortality [18]. There 
is a strong association between HCV infection and NODAT, 
particularly in patients receiving tacrolimus-based maintenance 
immunosuppressant [18]. Likewise, pretransplant HCV positive 
patients had a higher incidence of NODAT compared to patients 
without NODAT (OR: 11.15; 95% CI: 1.0051-106.19; p<0.05) in the 
present study. HCV infection is a potentially modifiable risk factor 
for NODAT after kidney transplantation. Successful pretransplant 
treatment of HCV could reduce the incidence of NODAT. 
In the present study, the incidence of AR episodes was higher in 
patients with NODAT (21.7% versus 9.3%; P>0.05). The possible 
reason might be the more usage of immunosuppressant including 
pulse therapy of methylprednisolone that results in increased 
incidences of NODAT. Moreover, the presence of NODAT itself can 
increase the risk of rejections [19]. The lack of significant association 
between some of the risk factors in the present study may be due to 
small sample size and follow-up for only 12 mo.  
CONCLUSION 
In conclusion, NODAT is still common in Indian kidney transplant 
recipients. The present study confirmed various demographic risk 
factors for NODAT such as positive family history and older 
recipients. The prevalence of potentially modifiable risk factors in 
our study cohort was overweight recipients and pretransplant HCV 
infection, serum triglycerides, and cholesterol levels. 
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